Following a limited submission
AWMSG advice |
|
| Status: Superseded | |
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2025. Refer to ID6378: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) |
|
Medicine details |
|
| Medicine name | abiraterone |
| Formulation | 250 mg and 500 mg tablet |
| Reference number | 6441 |
| Indication | With prednisolone for the treatment of newly-diagnosed high-risk, metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Limited |
| Status | Superseded |
| Scrutiny Panel meeting date | 09/01/2025 |
| LOWMAG meeting date | 07/04/2025 |
| AWMSG meeting date | 20/05/2025 |
| Date of issue | 29/05/2025 |
| NICE guidance | |
| Further information This medicine received a positive recommendation by AWMSG in May 2025, assessment reports are available upon request. |
|